These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28558669)

  • 1. Calretinin as a blood-based biomarker for mesothelioma.
    Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
    BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
    Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
    Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.
    Johnen G; Burek K; Raiko I; Wichert K; Pesch B; Weber DG; Lehnert M; Casjens S; Hagemeyer O; Taeger D; Brüning T;
    Sci Rep; 2018 Sep; 8(1):14321. PubMed ID: 30254313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.
    Casjens S; Weber DG; Johnen G; Raiko I; Taeger D; Meinig C; Moebus S; Jöckel KH; Brüning T; Pesch B
    BMJ Open; 2017 Oct; 7(10):e017104. PubMed ID: 29025836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.
    Jiménez-Ramírez C; Gilbert Weber D; Aguilar-Madrid G; Brik A; Juárez-Pérez CA; Casjens S; Raiko I; Brüning T; Johnen G; Cabello-López A
    PLoS One; 2022; 17(10):e0275936. PubMed ID: 36240245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.
    Aguilar-Madrid G; Pesch B; Calderón-Aranda ES; Burek K; Jiménez-Ramírez C; Juárez-Pérez CA; Ochoa-Vázquez MD; Torre-Bouscoulet L; Acosta-Saavedra LC; Sada-Ovalle I; García-Figueroa J; Alvarado-Cabrero I; Castillo-González P; Báez-Saldaña AR; Pérez-Padilla JR; Osnaya-Juárez J; Rivera-Rosales RM; García-Bazán EM; Bautista-Aragón YL; Lazcano-Hernandez E; Munguía-Canales DA; Argote-Greene LM; Taeger D; Weber DG; Casjens S; Raiko I; Brüning T; Johnen G
    Int J Med Sci; 2018; 15(9):883-891. PubMed ID: 30008600
    [No Abstract]   [Full Text] [Related]  

  • 7. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients.
    Raiko I; Sander I; Weber DG; Raulf-Heimsoth M; Gillissen A; Kollmeier J; Scherpereel A; Brüning T; Johnen G
    BMC Cancer; 2010 May; 10():242. PubMed ID: 20509881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
    Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
    Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
    BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.
    Weber DG; Casjens S; Johnen G; Bryk O; Raiko I; Pesch B; Kollmeier J; Bauer TT; Brüning T
    PLoS One; 2014; 9(12):e114483. PubMed ID: 25469901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
    Felten MK; Khatab K; Knoll L; Schettgen T; Müller-Berndorff H; Kraus T
    Int Arch Occup Environ Health; 2014 Feb; 87(2):195-204. PubMed ID: 23423281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
    Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H
    Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
    Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
    Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
    J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.
    Creaney J; Robinson BWS
    Chest; 2017 Jul; 152(1):143-149. PubMed ID: 28007619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of plasma calretinin in patients with malignant pleural mesothelioma.
    Lehnert M; Weber DG; Taeger D; Raiko I; Kollmeier J; Stephan-Falkenau S; Brüning T; Johnen G;
    BMC Res Notes; 2020 Jul; 13(1):359. PubMed ID: 32727552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
    Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.